Kissei Pharmaceutical: Launch of YSELTY (generic name linzagolix) for uterine fibroid treatment in Europe
Kissei Pharmaceutical: Announcement of the new sale of the uterine fibroid treatment drug Iserti (generic name Linzagolix) in Europe
Kissei Pharmaceutical: Drug discovery research collaboration agreement with Reborna Biosciences, Inc.
Kissei Pharmaceutical: Announcement of the conclusion of a drug discovery joint research agreement with Livorna Biosciences
Kissei Pharmaceutical: Licensing Agreement for "olutasidenib", an Acute Myeloid Leukemia Drug
Kissei Pharmaceutical: Notice of conclusion of a technology introduction agreement for the acute myeloid leukemia agent “ortacidenib”
Kissei Pharmaceutical: Supplementary explanatory materials related to the financial statements for the three-month period ending on June 30, 2024.
Kissei Pharmaceutical: Consolidated financial results for the three months ending on June 30, 2024 [Japanese standards]
Kissei Pharmaceutical: Announcements of individual stocks: Notice of signing a technology transfer contract with JW Pharma Co., Ltd. (South Korea) for Linzagolix.
Kissei Pharmaceutical: Licensing agreement for GnRH antagonist Linzagolix with South Korean pharmaceutical company JW Pharmaceuticals.
Kissei Pharmaceutical: Independent Officer Notification Form
Kissei Pharmaceutical: Financial briefings for the fiscal year ended 2024/3/31
Kissei Pharmaceutical: Consolidated financial results for the fiscal year ended 2024/3/31 [Japanese GAAP]
Kissei Pharmaceutical: Supplementary explanatory materials on financial results for the fiscal year ended 2024/3/31
Kissei Pharmaceutical: 2024 financial results overview
Kissei Pharmaceutical: Notice Concerning Status of Acquisition and Completion of the Company’s Own Shares
Kissei Pharmaceutical Industries: Notice Concerning Status of Share Repurchase
Kissei Pharmaceutical: Notice Concerning Status of Acquisition of the Company’s Own Shares
Kissei Pharmaceutical: Summary of Financial Results for the third quarter 2024
Kissei Pharmaceutical: Consolidated Financial Results for the Nine Months Ended December 31, 2023 [Japanese GAAP]
No Data
No Data